[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337619-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337619-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","regulation-of-pd-l1-expression-by-yy1-in-cancer-therapeutic-efficacy-of-targeting-yy1","Regulation of PD-L1 Expression by YY1 in Cancer - Therapeutic Efficacy of Targeting YY1","","During the last decade, resistant cancers have benefited from immunotherapeutic milestones that harness the host immune response against tumor-associated antigens and neoantigens. Responsive cytotoxic CD8+ T cells can control tumor growth, yet resistance arises when anti-tumor CD8+ T cells become dysfunctional in the tumor microenvironment. This dysfunction is driven in part by tumor-mediated activation of PD-1 via PD-L1, which checkpoint antibodies can block. An alternative strategy is explored: targeting the oncogenic transcription factor Yin Yang 1 (YY1) to regulate PD-L1 across transcriptional and post-transcriptional and post-translational levels, restoring CD8+ T-cell anti-tumor functions and supporting bioinformatic validation. YY1 also contributes to proliferation, invasion, EMT, metastasis, and chemo-immuno-resistance, suggesting broad anti-tumor therapeutic potential.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/regulation-of-pd-l1-expression-by-yy1-in-cancer-therapeutic-efficacy-of-targeting-yy1/337619/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/regulation-of-pd-l1-expression-by-yy1-in-cancer-therapeutic-efficacy-of-targeting-yy1/337619.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does PD-1/PD-L1 signaling play in anti-tumor CD8+ T-cell dysfunction?","Question",{"text":63,"@type":64},"PD-L1 expression by tumor or microenvironmental cells can activate the inhibitory receptor PD-1 on CD8+ T cells, impairing their anti-tumor function. This contributes to resistance against immune control of tumors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the document propose restoring CD8+ T-cell activity in resistant cancers?",{"text":68,"@type":64},"It describes two approaches: checkpoint inhibition that blocks PD-1/PD-L1 with monoclonal antibodies, and an alternative strategy that targets YY1 to prevent PD-L1 expression and restore CD8+ T-cell anti-tumor functions.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is YY1 considered a promising therapeutic target beyond PD-L1 regulation?",{"text":72,"@type":64},"The document reports that YY1 influences multiple anti-cancer–relevant processes, including proliferation and cell viability, invasion, epithelial–mesenchymal transition (EMT), metastasis, and chemo-immuno-resistance. Therefore, targeting YY1 could yield multiple anti-tumor effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337619,1790185066,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","cancers   \nReview  \nRegulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1  \nAna Dillen 1,†, Indy Bui 1,†, Megan Jung 1, Stephanie Agioti 2, Apostolos Zaravinos 2,3 and Benjamin Bonavida 1, *  \nCitation: Dillen, A.; Bui, I.; Jung, M.; Agioti, S.; Zaravinos, A.; Bonavida, B. Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1 . Cancers 2024, 16, 1237 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers16061237  \nAcademic Editor: Athanasios  \nG. Papavassiliou  \nReceived: 9 January 2024  \nRevised: 23 February 2024  \nAccepted: 11 March 2024  \nPublished: 21 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Microbiology, Immunology & Molecular Genetics, Jonsson Comprehensive Cancer, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; [anajae@g.ucla.edu](anajae@g.ucla.edu) (A.D.); [indybui500@gmail.com](indybui500@gmail.com) (I.B.)  \n2 Cancer Genetics, Genomic and Systems Biology Group, Basic and Translational Cancer Research Center (BTCRC), 1516 Nicosia, Cyprus; [a.zaravinos@euc.ac.cy](a.zaravinos@euc.ac.cy) (A.Z.)  \n3 Department of Life Sciences, School of Sciences, European University Cyprus, 2404 Nicosia, Cyprus  \n* [Correspondence: bbonavida@mednet.ucla.edu](Correspondence: bbonavida@mednet.ucla.edu)[ ](Correspondence: bbonavida@mednet.ucla.edu)† These authors contributed equally to this work.  \nSimple Summary: We have recently witnessed several milestones in the treatment of various cancers with immunotherapy through modulating the activity of the immune system to suppress and destroy cancer cells. One main factor involved in the anti-cancer immune system is cytotoxic immune cells known as T cells. T cells can recognize pathogenic cancer cells and launch targeted destruction attacks. However, these T cells may become non-functional due to their close association with cancer cells within the tumor microenvironment. Cancer cell activity can ultimately suppress T-cell function. New approaches that prevent the inactivation of T cells by cancer cells would result in recovery of the T-cell functions, cancer regression, and overall survival. Targeting cancer cells specifically to prevent T-cell inactivation would result in tumor disappearance, inhibition of metastasis, and the reversal of resistance to therapy. Therefore, this proposed alternative approach is promising as it is applicable to numerous cancers, including those that are resistant to treatment.  \nAbstract: During the last decade, we have witnessed several milestones in the treatment of various resistant cancers including immunotherapeutic strategies that have proven to be superior to conventional treatment options, such as chemotherapy and radiation. This approach utilizes the host’s immune response, which is triggered by cancer cells expressing tumor-associated antigens or neoantigens. The responsive immune cytotoxic CD8+ T cells specifically target and kill tumor cells, leading to tumor regression and prolongation of survival in some cancers; however, some cancers may exhibit resistance due to the inactivation of anti-tumor CD8+ T cells. One mechanism by which the anti-tumor CD8+ T cells become dysfunctional is through the activation of the inhibitory receptor programmed death-1 (PD-1) by the corresponding tumor cells (or other cells in the tumor microenvironment (TME)) that express the programmed death ligand-1 (PD-L1) . Hence, blocking the PD-1/PD-L1 interaction via specific monoclonal antibodies (mAbs) restores the CD8+ T cells’functions, leading to tumor regression. Accordingly, the Food and Drug","cbCait4WdLjWN86N","https://ap.wps.com/l/cbCait4WdLjWN86N","pdf",5908325,"English","# Introduction\n## Immunotherapy and resistance mechanisms\n## PD-1/PD-L1 checkpoint blockade\n## Targeting YY1 to regulate PD-L1\n## YY1 functions beyond PD-L1\n## Study rationale and bioinformatic exploration","[{\"question\":\"What role does PD-1/PD-L1 signaling play in anti-tumor CD8+ T-cell dysfunction?\",\"answer\":\"PD-L1 expression by tumor or microenvironmental cells can activate the inhibitory receptor PD-1 on CD8+ T cells, impairing their anti-tumor function. This contributes to resistance against immune control of tumors.\"},{\"question\":\"How does the document propose restoring CD8+ T-cell activity in resistant cancers?\",\"answer\":\"It describes two approaches: checkpoint inhibition that blocks PD-1/PD-L1 with monoclonal antibodies, and an alternative strategy that targets YY1 to prevent PD-L1 expression and restore CD8+ T-cell anti-tumor functions.\"},{\"question\":\"Why is YY1 considered a promising therapeutic target beyond PD-L1 regulation?\",\"answer\":\"The document reports that YY1 influences multiple anti-cancer–relevant processes, including proliferation and cell viability, invasion, epithelial–mesenchymal transition (EMT), metastasis, and chemo-immuno-resistance. Therefore, targeting YY1 could yield multiple anti-tumor effects.\"}]","Regulation of PD-L1 Expression by YY1 in Cancer - Therapeutic Efficacy of Targeting YY1 | PDF",1790019839,76,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26be0a56446906b9d5bf80f912046588.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5211601170c532fa16a54f3580951873.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6065c5e5eae307a2eac2b3f1888b799e.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb5e4b37c93bf6c7512d3747fea8cc2d.webp",980,1385]